Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) have been given an average rating of “Moderate Buy” by the six analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $11.43.
Several equities analysts have issued reports on ATNM shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. Maxim Group dropped their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday. Stephens began coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price objective for the company. HC Wainwright lowered their target price on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday.
Check Out Our Latest Research Report on Actinium Pharmaceuticals
Hedge Funds Weigh In On Actinium Pharmaceuticals
Actinium Pharmaceuticals Trading Up 14.8 %
Shares of NYSE ATNM opened at $2.41 on Friday. The stock has a market cap of $71.78 million, a PE ratio of -1.41 and a beta of 0.20. Actinium Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $10.24.
Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02. Equities analysts forecast that Actinium Pharmaceuticals will post -1.57 EPS for the current year.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.
Further Reading
- Five stocks we like better than Actinium Pharmaceuticals
- 5 Top Rated Dividend Stocks to Consider
- Owens-Corning Stock: Good Value or Recession Red Flag?
- Find and Profitably Trade Stocks at 52-Week Lows
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- What is Short Interest? How to Use It
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.